Gut microbiota patterns associated with somatostatin in patients undergoing pancreaticoduodenectomy: a prospective study.
Gut microbiota patterns associated with somatostatin in patients undergoing pancreaticoduodenectomy: a prospective study.
复制标题
接受胰十二指肠切除术的患者肠道微生物群模式与生长抑素相关:一项前瞻性研究
DOI:
10.1038/s41420-020-00329-4
复制
发表时间:
2020
影响因子:
7
通讯作者:
Sun B
中科院分区:
文献类型:
--
作者:
Li GQ;Zhang T;Yang WG;Zhong HL;Xiao P;Liu LW;Wang YW;Chen H;Kong R;Wang G;Tan HT;Bai XW;Li YL;Li L;Sun B
Postoperative pancreatic fistula (POPF) is a common and dreaded complication after pancreaticoduodenectomy (PD). The gut microbiota has been considered as an crucial mediator of postoperative complications, however, the precise roles of gut microbiota in POPF are unclear. A prospective study was developed to explore the effects of somatostatin on gut microbiota and we aim to identify the microbial alterations in the process of POPF. A total of 45 patients were randomly divided into PD group or additional somatostatin therapy group. The fecal sample of each patient was collected preoperatively and postoperatively and the gut microbiota was analyzed by 16S rRNA sequencing. Our study found that somatostatin therapy was independent risk factor for the occurrence of POPF, and it reduced the microbial diversity and richness in patients. At genus level, somatostatin therapy led to a decreased abundance in Bifidobacterium, Subdoligranulum and Dubosiella, whereas the abundance of Akkermansia, Enterococcus and Enterobacter were increased. The abundance levels of certain bacteria in the gut microbiota have significantly shifted in patients with POPF. The LEfSe analysis revealed that Ruminococcaceae could be used as microbial markers for distinguishing patients with high risk of POPF. Furthermore, Verrucomicrobia and Akkermansia could be used as preoperative biomarkers for identifying patients without POPF. Our prospective study highlights the specific communities related with somatostatin therapy and discovers POPF-associated microbial marker, which suggests that gut microbiota may become a diagnostic biomarker and potential therapeutic target for POPF.